comparemela.com

Latest Breaking News On - Barbara ann karmanos cancer - Page 2 : comparemela.com

Teclistamab Leads Ongoing Emergence of Bispecific Antibodies in Multiple Myeloma

Jeffrey Zonder, MD, discussed the ongoing development of other BCMA-targeted and non–BMCA targeted bispecific antibodies, toxicity management for these agents, how to navigate treatment decisions for patients eligible for CAR T-cell therapy, and ongoing research in multiple myeloma at the Barbara Ann Karmanos Cancer Institute.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.